At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed May 20, 2026 at 11:07 ET
MiNK Therapeutics presented a single-case report at ATS 2026 showing that sequential immunotherapy with Anktiva (N-803) and its iNKT cell therapy agenT-797 suppressed fungal/bacterial pathogens, activated immune cell recruitment, reduced inflammatory signaling, and triggered tissue repair pathways in a critically ill patient with disseminated valley fever, ARDS, and hospital-acquired pneumonia after standard-of-care failed. The data support an ongoing Phase 2 trial in severe acute lung injury, but limited to a single case without quantitative efficacy or survival endpoints.
- Case report: sequential Anktiva (N-803) + agenT-797 in critically ill patient with disseminated Coccidioides immitis, ARDS, and Pseudomonas pneumonia
- Observed: pathogen suppression, immune cell recruitment into lung, reduced early inflammatory signaling, activation of tissue repair pathways
- AgenT-797 already has prior safety data in moderate-severe ARDS (favorable safety, improved survival, decreased secondary infections per prior disclosure)
- MiNK recently initiated a randomized Phase 2 trial of agenT-797 in severe acute lung injury / critical illness
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access